Kathleen L Meert1, Jeff Clark, Ashok P Sarnaik. 1. Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA. kmeert@med.wayne.edu
Abstract
OBJECTIVE: 1) To alert the clinician that increasing rate and depth of breathing during treatment of acute asthma may be a manifestation of metabolic acidosis with hyperventilation rather than worsening airway obstruction; and 2) to describe the frequency of metabolic acidosis with hyperventilation in children with severe acute asthma admitted to our pediatric intensive care unit. DESIGN: Retrospective medical record review. SETTING: University-affiliated children's hospital. PATIENTS: All patients admitted to the pediatric intensive care unit with a diagnosis of asthma between January 1, 2005, and December 31, 2005. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Fifty-three patients with asthma (median age 7.8 yrs, range 0.7-17.9 yrs; 35 [66%] male; 46 [87%] black and 7 [13%] white) were admitted to the pediatric intensive care unit during the study period. Fifteen (28%) patients developed metabolic acidosis with hyperventilation (pH <7.35, Pco2 <35 torr [4.6 kPa], and base excess < or = -7 mmol/L) during their hospital course. Of these, lactic acid was assessed in four patients and was elevated in each; all had hyperglycemia (blood glucose >120 mg/dL [6.7 mmol/L]). Patients who developed metabolic acidosis with hyperventilation received asthma therapy similar to that received by patients who did not develop the disorder. Metabolic acidosis resolved contemporaneously with tapering of beta2-adrenergic agonists and administration of supportive care. All patients survived. CONCLUSIONS: Metabolic acidosis with hyperventilation manifesting as respiratory distress can occur in children with severe acute asthma. A pathophysiologic rationale exists for the contribution of beta2-adrenergic agents to the development of this acid-base disorder. Failure to recognize metabolic acidosis as the underlying mechanism of respiratory distress may lead to inappropriate intensification of bronchodilator therapy. Supportive care and tapering of beta2-adrenergic agents are recommended to resolve this condition.
OBJECTIVE: 1) To alert the clinician that increasing rate and depth of breathing during treatment of acute asthma may be a manifestation of metabolic acidosis with hyperventilation rather than worsening airway obstruction; and 2) to describe the frequency of metabolic acidosis with hyperventilation in children with severe acute asthma admitted to our pediatric intensive care unit. DESIGN: Retrospective medical record review. SETTING: University-affiliated children's hospital. PATIENTS: All patients admitted to the pediatric intensive care unit with a diagnosis of asthma between January 1, 2005, and December 31, 2005. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Fifty-three patients with asthma (median age 7.8 yrs, range 0.7-17.9 yrs; 35 [66%] male; 46 [87%] black and 7 [13%] white) were admitted to the pediatric intensive care unit during the study period. Fifteen (28%) patients developed metabolic acidosis with hyperventilation (pH <7.35, Pco2 <35 torr [4.6 kPa], and base excess < or = -7 mmol/L) during their hospital course. Of these, lactic acid was assessed in four patients and was elevated in each; all had hyperglycemia (blood glucose >120 mg/dL [6.7 mmol/L]). Patients who developed metabolic acidosis with hyperventilation received asthma therapy similar to that received by patients who did not develop the disorder. Metabolic acidosis resolved contemporaneously with tapering of beta2-adrenergic agonists and administration of supportive care. All patients survived. CONCLUSIONS:Metabolic acidosis with hyperventilation manifesting as respiratory distress can occur in children with severe acute asthma. A pathophysiologic rationale exists for the contribution of beta2-adrenergic agents to the development of this acid-base disorder. Failure to recognize metabolic acidosis as the underlying mechanism of respiratory distress may lead to inappropriate intensification of bronchodilator therapy. Supportive care and tapering of beta2-adrenergic agents are recommended to resolve this condition.
Authors: Lars W Andersen; Julie Mackenhauer; Jonathan C Roberts; Katherine M Berg; Michael N Cocchi; Michael W Donnino Journal: Mayo Clin Proc Date: 2013-10 Impact factor: 7.616
Authors: Christopher L Carroll; Melinda Coro; Allison Cowl; Kathleen A Sala; Craig M Schramm Journal: World J Pediatr Date: 2014-03-06 Impact factor: 2.764
Authors: Christopher J L Newth; Kathleen L Meert; Amy E Clark; Frank W Moler; Athena F Zuppa; Robert A Berg; Murray M Pollack; Katherine A Sward; John T Berger; David L Wessel; Rick E Harrison; Jean Reardon; Joseph A Carcillo; Thomas P Shanley; Richard Holubkov; J Michael Dean; Allan Doctor; Carol E Nicholson Journal: J Pediatr Date: 2012-04-10 Impact factor: 4.406
Authors: María M Adeva-Andany; Natalia Carneiro-Freire; Cristóbal Donapetry-García; Eva Rañal-Muíño; Yosua López-Pereiro Journal: Biomed Res Int Date: 2014-04-30 Impact factor: 3.411
Authors: Alina G Liedtke; Sebastiano A G Lava; Gregorio P Milani; Carlo Agostoni; Viola Gilardi; Mario G Bianchetti; Giorgio Treglia; Pietro B Faré Journal: J Clin Med Date: 2019-12-27 Impact factor: 4.241
Authors: Naomi Maldonado-Rodriguez; David J Bentley; Heather M Logan-Sprenger Journal: Int J Environ Res Public Health Date: 2022-02-24 Impact factor: 3.390